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Background: Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule
dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer
(MBC) after ≥1 prior chemotherapy for advanced disease, including an anthracycline and a taxane in either the adjuvant
or metastatic setting. Data from Studies 305 and 301 were pooled to investigate the efﬁcacy of eribulin in various sub-
groups of patients who matched the EU label, including those with human epidermal growth factor receptor 2 (HER2)-
negative and triple-negative disease.
Patients and methods: In Study 305 (NCT00388726), patients were randomized 2:1 to eribulin mesylate 1.4 mg/m2
(equivalent to eribulin 1.23 mg/m2 [expressed as free base]) intravenously on days 1 and 8 every 21 days] or treatment of
physician’s choice after 2–5 prior chemotherapies (≥2 for advanced disease), including an anthracycline and a taxane (in
early/advanced setting). In Study 301 (NCT00337103), patients were randomized 1:1 to eribulin (as above) or capecita-
bine (1.25 g/m2 orally twice daily on days 1–14 every 21 days) following ≤3 prior chemotherapies (≤2 for advanced
disease), including an anthracycline and a taxane. Efﬁcacy end points were investigated in the intent-to-treat population
and subgroups, pooled as discussed above.
Results: Overall, 1644 patients were included (eribulin: 946; control: 698); baseline characteristics were well matched.
Overall survival was signiﬁcantly longer with eribulin versus control (P < 0.01), as were progression-free survival and clinical
beneﬁt rate (both P < 0.05). Signiﬁcant survival beneﬁts with eribulin versus control were observed in a wide range of
patient subgroups, including HER2-negative or triple-negative disease (all P < 0.05).
Conclusion: Our ﬁndings underline the survival beneﬁt achieved by eribulin used according to EU label in the overall
MBC population and in various subgroups of interest, including patients with HER2-negative and triple-negative disease.
Key words:metastatic breast cancer, triple-negative breast cancer, eribulin, clinical trial, survival, pooled analysis
*Correspondence to: Prof. Xavier Pivot, Department of Oncology, Centre Hospitalier
Universitaire de Besançon, Service d’Oncologie Médicale, 3 bd Alexander Fleming,
Besançon cedex 25030, France.
Tel: +33-381-669-212; E-mail: xavierpivot@univ-fcomte.fr
Annals of Oncology original articles
©The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use,
please contact journals.permissions@oup.com
introduction
Long-term survival of women with advanced or metastatic
breast cancer (MBC) remains poor [1, 2] with no single accepted
standard of care once initial chemotherapy has failed [2, 3]. In
March 2011, the microtubule dynamics inhibitor eribulin mesy-
late (eribulin) was approved by the European Medicines Agency
(EMA) for the treatment of MBC in women who had received
two or more prior chemotherapy regimens for their disease.
This approval was based on results from a phase III, open-label,
randomized study (Study 305/EMBRACE), in which eribulin
was compared with treatment of physician’s choice (TPC) in
patients with locally recurrent or MBC who had received 2–5
prior chemotherapeutic regimens (including an anthracycline
and a taxane for early or advanced disease), with ≥2 che-
motherapies for advanced disease [4]. In this study, the median
overall survival (OS) was signiﬁcantly longer with eribulin than
with TPC [hazard ratio (HR) 0.81; 95% conﬁdence interval (CI)
0.67, 0.96; P = 0.014]. There was also a signiﬁcant difference in
favor of eribulin in progression-free survival (PFS), as assessed
by the investigators (HR 0.76; 95% CI, 0.64, 0.90; P = 0.002),
but not by independent review (HR 0.87; 95% CI 0.71, 1.05;
P = 0.137) [4].
In July 2014, the European Union (EU) indication for eribulin
was expanded to include patients with locally advanced or MBC
who had received one or more prior chemotherapeutic regimens
for advanced disease (including an anthracycline and a taxane
in either the adjuvant or metastatic setting, unless patients were
not suitable for these treatments) [5]. Support for this indication
came from Study 301, which compared eribulin with capecita-
bine in women with locally advanced or MBC receiving study
treatment as their ﬁrst-, second-, or third-line therapy, having
previously received an anthracycline and a taxane [6]. In this
study, a signiﬁcant survival beneﬁt for eribulin over capecitabine
was not demonstrated in the overall population (HR 0.88; 95%
CI 0.77, 1.00; P = 0.056); however, prespeciﬁed subgroup ana-
lyses showed a longer OS for eribulin compared with capecita-
bine in patients with human epidermal growth factor receptor 2
(HER2)-negative disease or triple-negative breast cancer (TNBC)
(Twelves et al., manuscript under review).
Two potential strategies to further investigate the differences
in treatment effect observed in a subgroup of interest may in-
clude the development of a new randomized clinical trial specif-
ically in this patient subgroup or a pooled analysis of relevant
clinical data—the latter approach was conducted upon a request
from the EMA. Data from Studies 305 and 301 were pooled to
investigate the efﬁcacy of eribulin in various subgroups of
patients, including those with HER2-negative and TNBC. This
ﬁrst analysis was carried out with 77% and 82% of events in
Studies 305 and 301, respectively [7]. Signiﬁcant improvements
in OS with eribulin versus the control arm were observed in
some subgroups, including HER2-negative disease (HR 0.82;
95% CI 0.72, 0.93; P = 0.002) and TNBC (HR 0.74; 95% CI 0.60,
0.92; P = 0.006).
To provide clinicians with additional evidence speciﬁc to the
patient population now approved in the EU for treatment with
eribulin, here we report the efﬁcacy of eribulin in patients
pooled from Studies 305 and 301 who matched the EU label.
The current analysis differs from the previous pooled analysis
[7] as it speciﬁcally assesses the efﬁcacy of eribulin in the patient
population deﬁned according to the EU label, and in subgroups
of interest (that were also investigated in the previous pooled
analysis) based on more updated data.
Table 1. Baseline demographics and disease characteristics for the
patients in the pooled analysis who received eribulin according to the
EU labela
Patient characteristics Eribulin (n = 946) Control (n = 698)
Study populationb 58% 43%
Age, years
Mean (SD) 55 (10.3) 54 (10.2)
Race
Black 32 (3.4) 24 (3.4)
White 860 (90.9) 639 (91.5)
Asian/Pacific Islander 20 (2.1) 17 (2.4)
Other 34 (3.6) 18 (2.6)
Site of disease
Visceral 782 (82.7) 608 (87.1)
Non-visceral 153 (16.2) 84 (12.0)
Missing 11 (1.2) 6 (0.9)
Number of organs involved
≤2 471 (49.8) 324 (46.4)
>2 475 (50.2) 374 (53.6)
Number of prior chemotherapy regimens
1 48 (5.1) 55 (7.9)
≥2 896 (94.7) 642 (92.0)
NA 2 (0.2) 1 (0.1)
Number prior chemotherapy regimen for locally advanced or metastatic
disease
0 1 (0.1) 0
1 288 (30.4) 300 (43.0)
≥2 657 (69.5) 397 (56.9)
NA — 1 (0.1)
HER2 status
Positive 150 (15.9) 104 (14.9)
Negative 663 (70.1) 497 (71.2)
Unknown 133 (14.1) 97 (13.9)
ER status
Positive 544 (57.5) 401 (57.4)
Negative 319 (33.7) 237 (34.0)
Unknown 83 (8.8) 60 (8.6)
PR status
Positive 435 (46.0) 320 (45.8)
Negative 397 (42.0) 288 (41.3)
Unknown 114 (12.1) 90 (12.9)
Triple negative 199 (21.0) 153 (21.9)
Data are n (%) unless stated otherwise.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2;
NA, not available; PR, progesterone receptor; SD, standard deviation.
aPatients with locally advanced or metastatic breast cancer who had
received one or more prior chemotherapeutic regimens for advanced
disease (including an anthracycline and a taxane in either the adjuvant
or metastatic setting, unless patients were not suitable for these
treatments).
bProportion of total patients.
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patients andmethods
Detailed methods for Studies 305 (NCT00388726) and 301
(NCT00337103) have been published previously [4, 6]. Brieﬂy, in the
open-label, randomized Study 305, patients were randomized 2:1 to eribu-
lin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 [expressed as
free base]) intravenously on days 1 and 8 every 21 days] or TPC (deﬁned as
any single-agent chemotherapy or hormonal or biological treatment; radio-
therapy; or symptomatic treatment alone) after 2–5 prior chemotherapies,
of which ≥2 were for locally recurrent or MBC, including an anthracycline
and a taxane (for early or advanced disease) [4]. Stratiﬁcation factors for
randomization included HER2 status, prior exposure to capecitabine, and
geographic region. OS and PFS were the primary and secondary objectives,
respectively [4].
Study 301 was an open-label, randomized study of eribulin (dosed as
above) compared with capecitabine (1.25 g/m2 orally twice daily on days
1–14 every 21 days; 1:1 randomization ratio) in patients who had received
≤3 prior chemotherapy regimens (with ≤2 for advanced or metastatic
disease) including prior therapy with an anthracycline and a taxane for
early or advanced disease [6]. Patients who had received prior capecitabine
treatment were excluded. Stratiﬁcation factors for randomization included
HER2 status and geographic region. The coprimary end points were OS
and PFS [6].
Informed consent was obtained from all patients for Studies 305 and 301,
and all procedures followed were in accordance with the ethical standards of
the responsible committee on human experimentation (institutional and na-
tional), the Helsinki Declaration of 1975, as revised in 2000 and 2008, and
guidelines of the International Conference for Harmonization of Good
Clinical Practice.
statistical analyses
The main objective of this pooled analysis was to assess OS and PFS in the
pooled intent-to-treat population in patients who had received ≥1 prior line
of chemotherapy in the advanced or metastatic setting, including prior ex-
posure to anthracycline and taxane, in concordance with the EU label. Data
were updated for Study 305 to 17 June 2013 after 95% of death events oc-
curred. For Study 301, data are to 12 March 2012 after 82% of death events
occurred. Investigator-assessed data were used for these analyses; independ-
ent assessments were only used for imputation for number of organs
involved in the case of missing values. HRs for OS were based on a Cox
model, with the study, prior capecitabine use, geographic region, and HER2
status used as stratiﬁcation factors (in relevant subgroup analyses). Estrogen-
receptor (ER) status and number of organs involved were used as covariates,
if appropriate, in the sensitivity analyses. P values were estimated using
stratiﬁed log-rank tests stratiﬁed as for HR. For the subgroup analyses,
patients were analyzed by HER2 status (positive, negative, or unknown), ER
status (positive, negative, or unknown), presence of TNBC, number of
organs involved (≤2, >2), and the presence of visceral disease. These sub-
group analyses were analyzed in patients who received eribulin versus the
‘control arm’ (which comprised patients treated with the comparator drug in
Studies 305 and 301), and also for eribulin versus capecitabine, speciﬁcally.
Interaction analyses with treatment*study were carried out for the overall
population using a Cox model that was stratiﬁed by region, prior capecita-
bine treatment, and HER2 status, and with treatment, study, and treatment*-
study as covariates. The estimate and inference were obtained within each
study before pooling. Both studies were randomized and the line of treat-
ment was balanced between the eribulin and control arms. Interaction ana-
lyses were also carried out for subgroup analyses using the Cox models
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Figure 1. OS curves in patients who received eribulin or the comparator drug according to the EU labela. Hazard ratio is estimated based on the Cox model
with stratiﬁcation factors of region, HER2 status, prior capecitabine use, and study. The median OS is adjusted by study. P value is estimated based on the strati-
ﬁed log-rank test. aPatients with locally advanced or MBC who had received one or more prior chemotherapeutic regimens for advanced disease (including an
anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments). CI, conﬁdence interval; EU,
European Union; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival.
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stratiﬁed as above, and with treatment, subgroup, and treatment*subgroup
as covariates.
results
The overall group consisted of 1644 patients who had previously
received at least one prior chemotherapy regimen for advanced
disease, and were included in this analysis [eribulin: n = 946;
control (TPC/capecitabine): n = 698]. Of these, 1160 patients
had HER2-negative disease and a total of 489 patients were
randomized to treatment with capecitabine in the control arm
(45 and 444 patients from Studies 305 and 301, respectively).
Baseline characteristics and demographics were generally
well matched between the two treatment arms (Table 1). Two
hundred and twenty patients who received the study treatments
as ﬁrst-line therapy in Study 301 were not included in the
current analysis.
In the overall group of 1644 patients who had received ≥1
prior chemotherapy regimens for advanced disease, OS was
signiﬁcantly longer in the eribulin versus the control arm (HR
0.85; 95% CI 0.76, 0.94; P < 0.01; Figure 1); the median OS was
15.0 months (inter-quartile range 17.3) versus 12.6 (inter-quar-
tile range 17.8) months, respectively. Treatment with eribulin
was also associated with a signiﬁcantly longer PFS compared
with the control arm (HR 0.87; 95% CI 0.78, 0.97; P < 0.05;
median PFS: 3.9 versus 3.2 months, respectively; Figure 2).
Inclusion of a treatment*study interaction term in the model for
OS or PFS conﬁrmed lack of statistical evidence for treatment
differences among Studies 305 and 301 (both P > 0.05). The ob-
jective response rate (ORR) was similar between the treatment
groups, whereas clinical beneﬁt rate was signiﬁcantly higher
with eribulin compared with the control (30% versus 27%, re-
spectively; P < 0.05; supplementary Table S1, available at Annals
of Oncology online).
patient subgroups by receptor status and disease
characteristics
In the 1160 patients with HER2-negative disease, OS was signiﬁ-
cantly longer with eribulin compared with the control arm (HR
0.84; 95% CI 0.74, 0.96; P < 0.01; median OS: 15.1 versus 12.0
months, respectively). Signiﬁcantly longer OS with eribulin
versus the control arm was also observed in the 352 patients
with TNBC (HR 0.72; 95% CI 0.57, 0.90; P < 0.01; median OS:
12.4 versus 8.1 months, respectively).
Signiﬁcant improvements were also observed in patients with
ER-negative disease (P < 0.001), those without TNBC (P < 0.05),
with >2 organs involved (P < 0.05), and in patients with visceral
disease (P < 0.05; Figure 3). No signiﬁcant interaction between
study and treatment was observed (P > 0.05), except in patients
with non-visceral disease (P < 0.05; data not shown).
Eribulin signiﬁcantly improved PFS compared with the
control arm in patients with HER2-negative (P < 0.01), TNBC
Subgroup HR (95% CI) Eribulin/Comp P value
– Events/n – – Median (months) –
Eribulin Comparator
826/946 592/698
131/150 86/104
579/663 425/497
467/544 322/401
285/319 218/237
177/199 141/153
649/747 451/545
697/782 519/608
121/153 68/84
400/471 273/324
426/475 319/374
375/433 258/314
0.2 0.5 1 2 5
451/513 334/384
3.9/3.2 0.017
3.7/4.2 0.970
3.7/2.9 0.007
4.1/3.4 0.031
3.2/2.8 0.061
2.8/2.5 0.028
4.1/3.7 0.100
3.7/3.1 0.176
4.4/3.4 0.022
4.2/4.0 0.116
3.6/2.8 0.072
4.1/3.4 0.106
3.7/3.0
0.87 (0.78, 0.97)
1.00 (0.75, 1.35)
0.83 (0.73, 0.95)
0.84 (0.72, 0.98)
0.83 (0.68, 1.00)
0.77 (0.60, 0.97)
0.90 (0.79, 1.02)
0.92 (0.81, 1.04)
0.68 (0.48, 0.95)
0.87 (0.74, 1.03)
0.86 (0.74, 1.01)
0.87 (0.73, 1.03)
0.86 (0.74, 1.00) 0.045
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Figure 2. PFS in patients who received eribulin according to the EU labela, based on investigator review. HR was estimated based on the Cox model without
covariates, with stratiﬁcation factors: study, region, HER2 status, and prior capecitabine use. For HER2 subgroup analysis, HER2 was not used as a stratiﬁcation
factor. P value is estimated based on the stratiﬁed log-rank test. aPatients with locally advanced or MBC who had received one or more prior chemotherapeutic
regimens for advanced disease (including an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these
treatments). bA signiﬁcant interaction between study and treatment was observed in this analysis when a treatment*study interaction term was used (P < 0.01;
data not shown). CI, conﬁdence interval; ER, estrogen receptor; EU, European Union; HER2, human epidermal growth factor receptor 2; HR, hazard ratio;
MBC, metastatic breast cancer; PFS, progression-free survival.
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(P < 0.05), ER-positive disease (P < 0.05), and in patients with
non-visceral disease (P < 0.05; Figure 2). A signiﬁcant inter-
action between study and treatment was only observed in the
patients with ER-positive disease when a treatment*study inter-
action term was used (P < 0.01; data not shown).
An additional analysis was conducted in patients with HER2-
negative/ER-positive disease, as summarized in Figures 2 and 3 and
supplementary Figure S1, available at Annals of Oncology online.
sensitivity analyses
A sensitivity analysis with covariates of ER status and the
number of organs involved was conducted for OS in the overall
population and in the subgroups. The ﬁndings were consistent
with the analyses without these added covariates (supplemen-
tary Figure S1, available at Annals of Oncology online).
Comparative analyses were also conducted in patients who
received eribulin versus capecitabine in the control arm, in the
pooled patient population. Overall, eribulin signiﬁcantly pro-
longed OS compared with capecitabine (HR 0.84; 95% CI 0.73,
0.96; P < 0.05; median OS: 15.2 versus 13.3 months, respectively).
A similar beneﬁt with eribulin compared with capecitabine was
also observed in many of the subgroups analyzed, including
patients with HER2-negative disease or TNBC (both P < 0.05;
supplementary Figure S2, available at Annals of Oncology online).
safety
For eribulin, the median number of treatment cycles was 5
(range, 1–65 cycles), and the median duration of treatment was
3.9 months (range, 0.7–45.1 months). For the comparator arm,
the median number of treatment cycles was 4 (range, 1–61
cycles), and the median duration of treatment was 3.1 months
(range, 0.03–51.8 months). Treatment emergent adverse events
(TEAEs) occurred in 901 (96.7%) of 932 patients receiving eri-
bulin and 629 (91.3%) of 689 patients in the comparator arm.
Serious TEAEs occurred in 199 (21.4%) of patients on eribulin
and 155 (22.5%) of those on the comparator, and TEAEs
leading to therapy discontinuation occurred in 105 (11.3%) of
eribulin patients and 94 (13.6%) of patients receiving compara-
tor. Both treatment arms had manageable safety proﬁles consist-
ent with their known TEAEs. TEAEs of any grade occurring in
>10% of either arm and grade 3 or 4 TEAEs occurring in >2% of
either arm are summarized in Table 2.
discussion
This pooled analysis evaluated the efﬁcacy of eribulin in 1644
patients with MBC who had received at least one prior chemo-
therapy regimen for advanced disease within the previously
reported Studies 301 [6] and 305 [4]. The current analysis spe-
ciﬁcally assesses the efﬁcacy of eribulin in the patient population
Subgroup HR (95% CI) Eribulin/Comp P value
– Events/n – – Median (months) –
Eribulin Comparator
844/946 621/698
136/150 97/104
590/663 442/497
118/133 82/97
484/544 348/401
285/319 225/237
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713/782 540/608
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0.2 0.5 1 2 5
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12.4/8.1 0.005
15.7/14.0 0.017
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Figure 3. OS in patients who received eribulin according to the EU labela. HR was estimated based on the Cox model without covariates, with stratiﬁcation
factors: study, region, HER2 status, and prior capecitabine use. For HER2 subgroup analysis, HER2 was not used as a stratiﬁcation factor. P value is estimated
based on the stratiﬁed log-rank test. aPatients with locally advanced or MBC who had received one or more prior chemotherapeutic regimens for advanced disease
(including an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments). bA signiﬁcant inter-
action between study and treatment was observed in this analysis (P < 0.05; data not shown). Intent-to-treat population. CI, conﬁdence interval; ER, estrogen recep-
tor; EU, European Union; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MBC, metastatic breast cancer; OS, overall survival.
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deﬁned according to the EU label, and in subgroups of interest
based on more updated data. The majority of patients in this
analysis received eribulin in the third-line or higher setting due
to the fact that all patients from Study 305 received treatment in
the third-line or higher setting as per the study design [4].
The limitations of this pooled analysis include that it was not
preplanned and the complicated nature of the pooling of data
because the patient groups from the two studies (Study 301 and
Study 305) varied in terms of the extent of prior chemotherapy.
However, the statistical models and analysis used took these dif-
ferences into account. Additionally, the two studies also differed
in their control arms––while Study 301 used capecitabine as the
active comparator, Study 305 used TPC. However, considering
the lack of data from prospective studies in patient populations
that match the current indication of eribulin [5], this pooled
analysis should provide clinicians with valuable additional data
to aid treatment decisions.
The statistically signiﬁcant differences observed in OS are a
strength of these pooled analyses, since OS has been the gold
standard end point in phase III oncology clinical trials since the
1980s [8]. While surrogate end points (e.g. PFS) can markedly
reduce the number of patients needed to detect a statistically
signiﬁcant beneﬁt (in comparison with OS analysis), meta-ana-
lyses have, however, shown that these are not always reliable and
PFS and OS may only weakly correlate [9, 10]. The poor correl-
ation between PFS and OS may be related to the composite
nature of PFS as an end point, cross-over, and poststudy antic-
ancer therapies [11].
In our pooled analysis, the median OS was signiﬁcantly
longer with eribulin compared with the control arm. The HRs
were similarly in favor of eribulin both in the overall analysis
and in the sensitivity analysis, which included ER status and the
number of organs involved as covariates due to the large treat-
ment effects observed. By adjusting for these factors, which are
also considered prognostic in patients with MBC [12], the sensi-
tivity analysis aimed to balance the impact of these two sub-
groups on the overall effects of treatment on OS. Treatment with
eribulin was also associated with signiﬁcantly longer PFS.
Treatment of HER2-positive tumors by chemotherapy alone
is considered when therapies comprising anti-HER2 agents are
contraindicated or not available. In contrast, chemotherapy is
the standard of care in patients with HER2-negative breast
cancer, which constitutes ∼85% of women with MBC [13], and
is associated with poor prognosis and limited effective treatment
Table 2. Treatment emergent adverse events occurring at >10% for any grade or >2% for grade 3 or 4
Eribulin (n = 932) Comparator (n = 689)
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Subjects with any TEAE 901 (96.7) 361 (38.7) 258 (27.7) 629 (91.3) 248 (36.0) 76 (11.0)
Subjects with any serious TEAE 199 (21.4) 83 (8.9) 49 (5.3) 155 (22.5) 60 (8.7) 38 (5.5)
Subjects with TEAEs leading to discontinuation 105 (11.3) 49 (5.3) 10 (1.1) 94 (13.6) 43 (6.2) 17 (2.5)
Neutropenia 500 (53.6) 218 (23.4) 208 (22.3) 142 (20.6) 53 (7.7) 20 (2.9)
Alopecia 361 (38.7) 0 0 42 (6.1) 0 0
Nausea 268 (28.8) 7 (0.8) 0 176 (25.5) 13 (1.9) 0
Peripheral neuropathya 266 (28.5) 64 (6.9) 4 (0.4) 87 (12.6) 10 (1.5) 0
Leukopenia 255 (27.4) 113 (12.1) 18 (1.9) 74 (10.7) 21 (3.0) 3 (0.4)
Fatigue 221 (23.7) 24 (2.6) 3 (0.3) 116 (16.8) 23 (3.3) 1 (0.1)
Asthenia 203 (21.8) 45 (4.8) 0 122 (17.7) 27 (3.9) 0
Anemia 177 (19.0) 17 (1.8) 1 (0.1) 133 (19.3) 11 (1.6) 2 (0.3)
Pyrexia 161 (17.3) 3 (0.3) 0 56 (8.1) 4 (0.6) 0
Diarrhea 158 (17.0) 4 (0.4) 1 (0.1) 174 (25.3) 27 (3.9) 1 (0.1)
Constipation 154 (16.5) 3 (0.3) 0 89 (12.9) 3 (0.4) 0
Headache 148 (15.9) 5 (0.5) 0 73 (10.6) 0 2 (0.3)
Vomiting 146 (15.7) 5 (0.5) 2 (0.2) 119 (17.3) 11 (1.6) 0
Dyspnea 129 (13.8) 29 (3.1) 4 (0.4) 79 (11.5) 19 (2.8) 7 (1.0)
Back pain 124 (13.3) 9 (1.0) 2 (0.2) 49 (7.1) 5 (0.7) 1 (0.1)
Weight decreased 124 (13.3) 3 (0.3) 0 53 (7.7) 1 (0.1) 0
Cough 113 (12.1) 4 (0.4) 0 57 (8.3) 1 (0.1) 0
Arthralgia 106 (11.4) 5 (0.5) 1 (0.1) 34 (4.9) 3 (0.4) 0
Anorexia 101 (10.8) 2 (0.2) 0 32 (4.6) 3 (0.4) 0
Bone pain 97 (10.4) 15 (1.6) 0 57 (8.3) 6 (0.9) 0
Pain in extremity 94 (10.1) 8 (0.9) 0 47 (6.8) 5 (0.7) 0
Decreased appetite 73 (7.8) 2 (0.2) 0 70 (10.2) 7 (1.0) 0
Alanine aminotransferase increased 60 (6.4) 23 (2.5) 0 20 (2.9) 2 (0.3) 0
Febrile neutropenia 32 (3.4) 22 (2.4) 9 (1.0) 9 (1.3) 4 (0.6) 5 (0.7)
Palmar-plantar erythrodysesthesia syndrome 8 (0.9) 2 (0.2) 0 240 (34.8) 72 (10.4) 0
aPeripheral neuropathy combines the following preferred terms: peripheral neuropathy, neuropathy peripheral, neuropathy, peripheral motor neuropathy,
polyneuropathy, peripheral sensory neuropathy, peripheral sensorimotor neuropathy, demyelinating polyneuropathy, and paraesthesia.
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options [14]. Clinical studies of eribulin in the context of tar-
geted HER2 are ongoing and should provide additional insight
for eribulin treatment of HER2-positive tumors. Given that
patients with HER2-negative disease represented a large subset
of the population in Studies 305 and 301, and HER2 status was
a stratiﬁcation factor in both, the current analysis of this sub-
group is of interest, and seems both robust and valuable. The
current analysis demonstrated that eribulin substantially im-
proved OS compared with control treatments in this subgroup
of pooled patients, irrespective of the analysis model used.
In our pooled analysis, beneﬁts with eribulin compared with
the control were also observed in other subgroups of interest,
such as patients with TNBC or ER-negative disease, with these
improvements again achieving nominal statistical signiﬁcance.
Capecitabine, as a single agent, is a commonly used option
beyond ﬁrst-line treatment. As patients treated with capecitabine
represented the largest subgroup in terms of treatment type in the
comparator arm in this analysis, it allowed for comparisons to
be made versus the patients treated with eribulin. The pooled
analysis of all patients treated with eribulin versus capecitabine
represents an interesting set of data to help place eribulin in the
hierarchy of treatment. Ultimately, the choice to administer eribu-
lin in the second line or higher setting will likely depend on
both patient preference and toxicity proﬁle following exposure to
ﬁrst-line treatment. Our pooled analyses suggest that treatment
with eribulin compared with capecitabine signiﬁcantly improves
OS. The eribulin beneﬁts were maintained in subgroups of patients
with HER2-negative, ER-negative, or TNBC disease, among others,
suggesting a tendency for longer survival outcomes with eribulin
compared with capecitabine.
conclusions
These data provide an assessment of the efﬁcacy of eribulin in
patients with MBC which matched the EU label. In this pooled
analysis, eribulin was associated with longer OS than the control
arm in the overall patient population and in various subgroups,
including patients with HER2-negative disease and TNBC. Our
dataset is extensive and the analyses appear to be robust with
eribulin repeatedly demonstrating a survival beneﬁt in compari-
son with control treatment. Our ﬁndings support the use of eri-
bulin earlier in the treatment paradigm for patients with MBC
that matched the target population as deﬁned in the EU label.
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